

NSGO EARLY PHASE CLINICAL TRIALS UPDATE







Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.

ENGOT-OV24 - NSGO / AVANOVA

EudraCT number: 2014-004269-26

ASCO 2016

Gynecologic Cancer

Session Type: Poster Session Date and Time: 06/06/2016 1:00 PM - 4:30 PM Abstract Title: The ENGOT-OV24/AVANOVA1 trial Abstract ID: 5555


Sponsor: NSGO Project Manager: Louisa Boufercha Statistitian: DePont Christensen PI: Mirza



ENGOT-OV24 - NSGO / AVANOVA

Phase 1 (Completed)

Dose Escalation from cohorts 1 to 2 to 3 to 4




Recommended Phase 2 Dose (RP2D) of bevacizumab-niraparib combination Niraparib 300mg daily + Bevacizumab 15mg/kg q 3 wks

mansoor@rh.regionh.dk



ENGOT-OV24 - NSGO / AVANOVA

Phase 2 design



- Stratifications
- BRCA status: BRCA mutated vs. non-carrier
- Prior receipt of anti-angiogenic therapy (yes/no)
- Prior lines of therapy: 1-3 vs > 3 lines

mansoor@rh.regionh.dk



Study Status

Part 1 Completed

Part 2Screening in DKActivations ongoing in SWESubmissions completed in (NOR, FIN)FDA & IRB submissions in May



A Phase 2 Randomized Umbrella Trial in Recurrent Ovarian Cancer NSGO-OV-UMB1 ENGOT-OV30

Sponsor:Nordic Society of Gynaelogical Oncology (NSGO)Study Chair:MR Mirza

Lead Investigators by participating groups:

MR Mirza: Nordic Society of Gynaecological Oncology (NSGO) The Scottish Gynaecological Cancer Trials Group (SGCTG) C Gourley: The Princess Margaret Hospital Consortium (PMHC) A Oza: I Vergote: Belgian Gynaelogical Onology Group (BGOG) M Friedlander: The Australia New Zealand Gynaecological Oncology Group (ANZGOG) J Barek: Cooperative Ovarian Cancer Group for Immunotherapy (COGI) Gynecologic Oncology Trial and Investigation Consortium (GOTIC) K Fujiwara: SY Ryu: Korean Gynaelogical Onology Group (KGOG) G Coukos Ludvig Cancer Research Centre, Switzerland









University Health Netwo





NSGO-OV-UMB1

Primary endpoint:

Progression-Free Survival (PFS) by RECIST

Endpoints


Secondary endpoints:

PFS by Immune-RECIST PFS at 9 months PFS at 12 months Median PFS PFS in each group according to trial stratification factors Overall survival for each experimental arm Objective response rate (ORR) Disease control rate (DCR) (CR+PR+SD) Duration of (Overall) Response Patient Related Outcomes (PROs) Safety and tolerability.



NSGO-OV-UMB1 Key Inclusion Criteria

- Relapsed ovarian cancer with TFIchemo either < 6months or ≥ 6months. Patients with TFIchemo of ≥ 6months must have received 3 courses of chemotherapy.
- High-grade serious, endometriod, undifferentiated. Apart from these types a limited number of low grade serious carcinoma, clear-cell carcinoma and mucinous carcinoma can be enrolled in this study - maximum of 5 patients per study cohort.
- Patient agrees to undergo all analysis (blood, serum, tissue) including tumor biopsy.
- ECOG performance status 0-1
- Serum albumin >30g/l.





NSGO-OV-UMB1 Experimental Treatment Arms

Abbreviations: C=cycle; D=day; IBW=ideal body weight; IV=intravenous; PO=by mouth.

								_																													I
	7-day Lead-In							Treatment Cycle 1 (and beyond) 28 days																													
								C1 Week 1							C1 Week 2								C1 Week 3						C1 Week 4								
	D	D	D	D	D	D	D	D								D							D							D							
	- 7	- 6	- 5	- 4	- 3	-2	- 1	1								8							1 5							2 2							
Treatment cohort A: MEDI4736 alone																																					
MEDI4736 (10mg/kg IV)								x															x														
	Treatment cohort B: AZD5069 in combination with MEDI4736																																				
AZD5069 (mg BID, PO)	x x	x x	x x	x x	x x	x x	X X	X X			x x							X X		X X		x x		x x		x x	X X		x x	x x		x x					
Medi4736 (mg/kg IV)								x															x														
	_					Т	reat	men	t co	hort	C:	AZI	D 91	50 i	n co	omb	ina	tion	n wit	th N	ИЕГ	147	36														
AZD9150 (mg/kg IBW IV)	x		X		x			x								x								x							x						
Medi4736 (mg/kg IV)								x	-															x													



NSGO-OV-UMB1 Study Status

- Initial grant from AZ received
- Kickoff meeting of Steering Committee Meeting (Feb 20, 2016, London)
- Major grant application for study cohorts A-C submitted (March 1, 2016)
- Distribution of responsibilities being agreed between the lead groups & sponsor (NSGO)
- Planned submissions June 2016

Next wave of molecules/combinations under discussion










A randomized double-blind placebo-controlled phase II trial of first-line combination chemotherapy with Nintadenib for patients with advanced or recurrent endometrial cancer



A randomized double-blind placebo-controlled phase II trial of first-line combination chemotherapy with Nintadenib for patients with advanced or recurrent endometrial cancer ENGOT-EN1 / FANDANGO

Study Status

- Feasibility in collaborative groups completed
- Intergroup contracts being signed
- **NSGO site-contracts being signed**
- Submissions DK (DHMA & VEK) completed
- Submissions SE (CA & EC) completed
- Submissions to other countries to follow

(GSO(FIN, NOR, BEL) GINECO, NOGGO)

ALMAC (drug supply): ready by mid July 2016 Expected first patient in: August/September 2016








A randomized phase II trial of Palbociclib in combination with letrozole versus letrozole for

patients with oestrogen receptor positive recurrent endometrial cancer.

ENGOT-EN3-NSGO/PALEO



mansoor@rh.regionh.dk

A randomized phase II trial of Palbociclib in combination with letrozole versus letrozole for patients with oestrogen receptor positive recurrent endometrial cancer.

ENGOT-EN3-NSGO/PALEO

Study Status

Feasibility is being performed Planned Submission starts in May-June 2016 Planned first Patient in: October 2016